https://orcid.org/0000-0002-4260-7607
References
- Pan American Health Organization. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas). PAHO/WHO | SIREVA II (Spanish only); Washington, D.C., United States of America; [accessed 2021 Mar 1]. https://www.paho.org/hq/index.php?option=com_content&view=article&id=5536:2011-sireva-ii&Itemid=3966&lang=en.
- Pastor L, Sings H, Hilton B, Kohli M, Kruse M, Wasserman M. A systematic review of pneumococcal conjugate vaccine (PCV) impact on acute otitis media (OM) and nasopharyngeal carriage (NP) due to nontypeable haemophilus influenza (NTHi). 35th annual meeting of the European society for paediatric infectious diseases; 2017; Madrid, Spain.
- Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657–2. doi:10.1371/journal.pmed.1001657.
- Dagan R, van der Beek BA, Ben-Shimol S, Pilishvili T, Givon-Lavi N. Effectiveness of the seven- and thirteen valent pneumococcal conjugate vaccines against vaccine-serotype otitis media. Clin Infect Dis. 2021. doi:10.1093/cid/ciab066.
- Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, Zollo A, Icardi G. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to the 10-valent pneumococcal conjugate vaccine (PCV10) in Italy. Pathogens. 2020;9(2):76. doi:10.3390/pathogens9020076.
- Perdrizet J, Lai YS, Williams S, Struwig VA, Wasserman M. Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia. Infect Dis Ther. 2021;10(1):507–20. doi:10.1007/s40121-021-00409-7.
- Pugh S, Wasserman M, Moffatt M, Marques S, Reyes JM, Prieto VA, Reijnders D, Rozenbaum MH, Laine J, Åhman H, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and The Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020;9(2):305–24. doi:10.1007/s40121-020-00287-5.
- Shafie AA, Ahmad N, Naidoo J, Foo CY, Wong C, Pugh S, Tan KK. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Hum Vaccin Immunother. 2020;16(7):1719–27. doi:10.1080/21645515.2019.1701911.
- Wasserman M, Palacios MG, Grajales AG, Baez FB, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560–69. doi:10.1080/21645515.2018.1516491.
- Wilson M, Wasserman M, Jadavi T, Postma M, Breton M-C, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018;7(3):353–71. doi:10.1007/s40121-018-0206-1.
- World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper. Wkly Epidemiol Rec. 2019;94(8):85–104.